Pfizer plays hardball in weight-loss drug fight
FT News Briefing
Forhecz Topher
4.4 • 1.2K Ratings
🗓️ 4 November 2025
⏱️ 11 minutes
🧾️ Download transcript
Summary
Palantir lifted its 2025 revenue guidance and Pfizer has filed a second lawsuit against Novo Nordisk and obesity drug start-up Metsera. Plus, OpenAI inked a $38bn computing deal with Amazon, and the FT’s Claire Jones explains how the Trump administration is considering pushing for wider global dollar adoption.
Mentioned in this podcast:
Palantir lifts 2025 sales outlook after posting strong quarterly growth
Pfizer files second lawsuit to block Novo Nordisk’s $9bn Metsera bid
OpenAI strikes $38bn computing deal with Amazon
US pushes for wider global dollar adoption
Today’s FT News Briefing was produced by Sonja Hutson, and Marc Filippino. Our show was mixed by Kelly Garry. Additional help from Michela Tindera, Michael Lello and David da Silva. The FT’s acting co-head of audio is Topher Forhecz. The show’s theme music is by Metaphor Music.
Read a transcript of this episode on FT.com
Hosted on Acast. See acast.com/privacy for more information.
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Good morning from the Financial Times. Today is Tuesday, November 4th, and this is your FT News briefing. |
| 0:08.0 | Palantir continues to ride high and two drug makers are going head to head and getting the courts involved. |
| 0:16.0 | In Farmerland right now, investors really only care about one thing, which is, do you have a weight |
| 0:23.5 | loss drug or do you have a next generation weight loss drug? |
| 0:27.1 | Plus, China is trying to get countries to ditch the U.S. dollar and the White House is pushing |
| 0:32.4 | back. |
| 0:34.0 | I'm Mark Filipino, and here's the news you need to start your day. |
| 0:44.7 | Thank you. I'm Mark Filipino, and here's the news you need to start your day. The good times keep on rolling for Palantir. |
| 0:47.5 | The data intelligence company boosted its sales guidance for 2025 yesterday. |
| 0:52.5 | The projection went from a little more than $4 billion to $4.4.4 billion, |
| 0:57.3 | which is more than what Wall Street was expecting. Palantir is another company riding the |
| 1:02.2 | artificial intelligence wave. It sells AI software to businesses and governments around the world |
| 1:07.3 | to process data. And it's a quiet stock market darling. |
| 1:11.9 | Palantir share price is up more than 170% this year. |
| 1:15.6 | Its market cap is close to $500 billion. |
| 1:24.6 | There's a legal showdown brewing over a pharmaceutical merger in the U.S. |
| 1:29.1 | Pfizer has filed two lawsuits to stop its Danish rival Novo Nordisk from buying the American |
| 1:34.6 | biotech company Metzara. |
| 1:36.9 | Metzera is developing next generation weight loss treatments. |
| 1:40.6 | Pfizer is alleging the merger would violate anti-competition laws. |
| 1:44.8 | Here to tell us more is Oliver Barnes, who's the FTZUS Deals and Activism Correspondent. |
| 1:49.4 | Hi, Oliver. |
... |
Transcript will be available on the free plan in 6 days. Upgrade to see the full transcript now.
Disclaimer: The podcast and artwork embedded on this page are from Forhecz Topher, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Forhecz Topher and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.